Clinical Trial Update: Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A0107 [Phase 3]

View source ↗

Summary

A Phase 3 follow-up study evaluating the safety of enteric-coated mycophenolate sodium in renal transplant recipients who completed the prior CERL080A0107 trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Transplantation

Drugs mentioned

• Enteric-coated mycophenolate sodium (Myfortic) (mycophenolate mofetil)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Renal Transplant | Phase 3 | Status: COMPLETED